Tudor Investment Corp’s Xenon Pharmaceuticals XENE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$28.8M Buy
495,591
+241,589
+95% +$11.1M 0.05% 288
2025
Q4
$11.4M Buy
254,002
+177,178
+231% +$7.44M 0.02% 662
2025
Q3
$3.08M Buy
+76,824
New +$2.71M 0.01% 1519
2025
Q1
Sell
-8,671
Closed -$340K 3776
2024
Q4
$340K Sell
8,671
-28,016
-76% -$1.16M ﹤0.01% 2511
2024
Q3
$1.44M Buy
36,687
+11,455
+45% +$462K 0.01% 1406
2024
Q2
$984K Buy
25,232
+75
+0.3% +$3K 0.01% 1467
2024
Q1
$1.08M Sell
25,157
-18,064
-42% -$831K 0.01% 1299
2023
Q4
$1.99M Buy
+43,221
New +$1.53M 0.02% 1097
2023
Q2
Sell
-29,908
Closed -$1.07M 3002
2023
Q1
$1.07M Buy
+29,908
New +$1.1M 0.02% 1153
2022
Q3
Sell
-20,336
Closed -$619K 2767
2022
Q2
$619K Buy
+20,336
New +$615K 0.02% 1150

Other funds holding XENE

Tudor Investment Corp's XENE Position: Q1 2026 in Review

Tudor Investment Corp increased its Xenon Pharmaceuticals (XENE) stake by 95% in Q1 2026, buying an estimated $11.1M and bringing the position to 495,591 shares worth $28.8M. The position accounts for 0.05% of the portfolio, ranked #288.

Tudor Investment Corp first reported a position in XENE in Q2 2022 and has held it in 10 quarters since. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Tudor Investment Corp held 495,591 shares of Xenon Pharmaceuticals worth $28.8M as of Q1 2026.
  • Tudor Investment Corp bought 241,589 Xenon Pharmaceuticals shares in Q1 2026, an estimated $11.1M.
  • Xenon Pharmaceuticals made up 0.05% of Tudor Investment Corp's portfolio in Q1 2026, its #288 holding.
  • Tudor Investment Corp first reported a position in Xenon Pharmaceuticals in Q2 2022 and has held it in 10 quarters since.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.